How often should women take the HIV prevention pill? a new study aims to find out

NCT ID NCT05057858

Completed Prevention Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how often cisgender women in Kenya need to take the HIV prevention pill Truvada (TDF-FTC) to keep protective drug levels in their blood. Participants are randomly assigned to take 2, 4, or 7 doses per week for up to 16 weeks, and their drug levels are measured. The study also explores how pregnancy may affect these levels, to help guide PrEP dosing recommendations for pregnant women.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Truvada (tenofovir disoproxil fumarate and emtricitabine)
What this could lead to: If successful, this study could help define the optimal dosing schedule for oral PrEP to prevent HIV in cisgender women, including during pregnancy.
What could go wrong: This is a small Phase 2 study focused on drug levels, not on actual HIV prevention outcomes. Results may not translate to real-world adherence or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Kenya Medical Research Institute - Partners in Health Research and Development

Thika, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.